初治肺结核应用预防性保肝治疗的疗效及肝损害情况分析  

Analysis of the effect of preventive hepatoprotective treatment on patients with newly treated pulmonary tuberculosis and liver damage

作　　者：邓建仟 黄芬[1] 刘建锋[1] 胡艳艳 Deng Jianqian;Huang Fen;Liu Jianfeng(The Jiangxi Province Chest Hospital,Nanchang,Jiangxi 330006)

机构地区：[1]江西省胸科医院,江西南昌330006 [2]奉新县人民医院,江西奉新330700

出　　处：《基层医学论坛》2023年第19期32-35,共4页The Medical Forum

摘　　要：目的观察初治肺结核应用预防性保肝治疗对疗效及肝损害情况的影响。方法研究病例为我院2020年1月-2021年5月期间收治的初治肺结核患者共132例,采用随机数字表法分为观察组66例与对照组66例。2组患者入院后均给予标准化疗方案治疗,对照组给予卡介菌多糖核酸治疗,观察组在对照组基础上给予预防性保肝治疗。观察2组疗效、肝损害情况、痰菌转阴情况及肝功能指标变化情况。结果观察组临床总有效率为93.94%,高于对照组的72.73%(P<0.05);观察组肝损害发生率为13.64%,低于对照组的42.42%(P<0.05);观察组痰涂片转阴率为100.00%,高于对照组的78.79%(P<0.05);治疗前,2组ALT、TBIL、AST水平无统计学差异(P>0.05);治疗后,观察组均低于对照组(P<0.05)。结论预防性保肝治疗可有效提高初治肺结核患者临床疗效,减轻肝损害,并提高痰涂片转阴率,还可改善患者肝功能,值得推广。Objective e To observe the effects of preventive hepatoprotective treatments for newly treated pulmonary tuberculosis on patients'curative effect and liver damage.Methods The study cases were all 132 newly-treated pulmonary tuberculosis patients who were admitted to our hospital from January 2020 to May 2021.They were divided into a study group of 66 cases and a control group of 66 cases by random number table.The two groups of patients were admitted to the hospital.All were treated with standard chemotherapy regimens,the control group was given BCG polysaccharide nucleic acid therapy,and the study group was given preventive hepatoprotective treatment on the basis of the control group.The curative effect,liver damage,sputum negative status and liver of the two groups were observed after treatment.Changes in functional indicators.Results The total clinical effective rate of the observation group(93.94%)is better than that of the control group(72.73%)(P<0.05);the total liver damage rate of the observation group(13.64%)is lower than that of the control group(42.42%)(P<0.05);The negative conversion rate of sputum smear(100.00%)was higher than that of the control group(78.79%)(P<0.05);there was no significant difference in the levels of ALT,TBIL and AST between the two groups before treatment(P>0.05),and the observation group after treatment The levels of ALT,TBIL and AST were lower than those of the control group(P<0.05).Conclusion Preventive hepatoprotective treatment measures can effectively improve the clinical efficacy of newly treated pulmonary tuberculosis patients,reduce liver damage,increase the rate of sputum smear conversion,and improve the liver function of patients.It is worthy of clinical widespread promotion and application.

关 键 词：初治肺结核 预防性保肝 治疗效果 肝损害 

分 类 号：R521.1[医药卫生—内科学] R452[医药卫生—临床医学]